Zacks Research Cuts Earnings Estimates for DENTSPLY SIRONA

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) – Investment analysts at Zacks Research lowered their Q1 2026 earnings estimates for shares of DENTSPLY SIRONA in a research note issued on Thursday, March 19th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $0.32 per share for the quarter, down from their previous estimate of $0.38. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for DENTSPLY SIRONA’s current full-year earnings is $1.84 per share. Zacks Research also issued estimates for DENTSPLY SIRONA’s Q2 2026 earnings at $0.38 EPS, Q3 2026 earnings at $0.36 EPS, Q4 2026 earnings at $0.38 EPS, FY2026 earnings at $1.43 EPS, Q1 2027 earnings at $0.33 EPS, Q2 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.43 EPS, FY2027 earnings at $1.56 EPS and FY2028 earnings at $1.73 EPS.

A number of other equities analysts have also issued reports on the company. Robert W. Baird raised their target price on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Wells Fargo & Company boosted their price target on DENTSPLY SIRONA from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 27th. Barclays assumed coverage on DENTSPLY SIRONA in a report on Monday, December 8th. They issued an “underweight” rating and a $12.00 price objective on the stock. Bank of America upgraded DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $13.00 to $17.00 in a research note on Thursday, February 19th. Finally, Mizuho lifted their target price on DENTSPLY SIRONA from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Monday, March 2nd. Three research analysts have rated the stock with a Buy rating, ten have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $14.42.

DENTSPLY SIRONA Trading Down 2.8%

NASDAQ:XRAY opened at $10.95 on Friday. The company has a market capitalization of $2.19 billion, a P/E ratio of -3.65, a PEG ratio of 1.32 and a beta of 0.97. The company has a current ratio of 1.51, a quick ratio of 1.03 and a debt-to-equity ratio of 1.50. DENTSPLY SIRONA has a 12 month low of $9.85 and a 12 month high of $17.18. The firm has a fifty day simple moving average of $12.65 and a 200-day simple moving average of $12.31.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Thursday, February 26th. The medical instruments supplier reported $0.27 earnings per share for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.85% and a negative net margin of 16.25%.The company had revenue of $961.00 million for the quarter, compared to analysts’ expectations of $926.40 million. During the same period in the prior year, the firm posted $0.26 EPS. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Mitsubishi UFJ Trust & Banking Corp raised its position in shares of DENTSPLY SIRONA by 1,836.7% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 105,938 shares of the medical instruments supplier’s stock worth $1,344,000 after purchasing an additional 100,468 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in DENTSPLY SIRONA by 38.4% in the 3rd quarter. Commonwealth Equity Services LLC now owns 804,934 shares of the medical instruments supplier’s stock worth $10,215,000 after buying an additional 223,339 shares during the last quarter. CWM LLC increased its stake in DENTSPLY SIRONA by 84.3% during the 3rd quarter. CWM LLC now owns 420,470 shares of the medical instruments supplier’s stock worth $5,336,000 after buying an additional 192,373 shares in the last quarter. Advisors Asset Management Inc. increased its stake in DENTSPLY SIRONA by 42.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 348,989 shares of the medical instruments supplier’s stock worth $4,429,000 after buying an additional 104,588 shares in the last quarter. Finally, Invenomic Capital Management LP raised its holdings in shares of DENTSPLY SIRONA by 48.7% during the third quarter. Invenomic Capital Management LP now owns 4,351,199 shares of the medical instruments supplier’s stock valued at $55,217,000 after acquiring an additional 1,425,637 shares during the last quarter. 95.70% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Gregory T. Lucier acquired 15,000 shares of DENTSPLY SIRONA stock in a transaction on Monday, March 9th. The stock was acquired at an average price of $12.45 per share, for a total transaction of $186,750.00. Following the purchase, the director owned 65,000 shares of the company’s stock, valued at approximately $809,250. This represents a 30.00% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director James D. Forbes acquired 5,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The stock was bought at an average cost of $12.48 per share, with a total value of $62,400.00. Following the acquisition, the director owned 10,000 shares in the company, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 70,000 shares of company stock worth $956,437 over the last ninety days. 0.50% of the stock is owned by insiders.

DENTSPLY SIRONA News Summary

Here are the key news stories impacting DENTSPLY SIRONA this week:

• Positive Sentiment: Investors are reacting to DENTSPLY SIRONA’s launch of a first‑of‑its‑kind dental MRI platform, which could expand the company’s addressable market and drive future equipment and service revenue. How Investors Are Reacting To DENTSPLY SIRONA (XRAY) Launching a First-of-Its-Kind Dental MRI Platform
• Positive Sentiment: Zacks raised its Q4 2026 EPS forecast to $0.38 from $0.34, a modestly constructive revision that could help offset some of the negative near‑term cuts if realized.
• Neutral Sentiment: Zacks published longer‑range FY2028 EPS of $1.73 (and still has a “Hold” rating), indicating some confidence in recovery further out but not an upgrade to a buy stance.
• Neutral Sentiment: Reported short‑interest data in the feed is anomalous (shows 0 shares / NaN change), so it provides no clear signal about bearish positioning or squeeze risk at this time.
• Negative Sentiment: Multiple near‑term estimate cuts from Zacks are the main bearish driver: they trimmed Q1–Q3 2026 and several 2027 quarterly forecasts and cut FY2026 EPS to $1.43 (from $1.50) and FY2027 to $1.56 (from $1.66). Those downward revisions reduce near‑term earnings visibility and likely pressured the stock today.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.